Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, controlled, parallel arm, PROBE study to evaluate different effects of imidapril and candesartan [candesartan cilexetil] on fibrinolysis and insulin-sensitivity in patients with mild to moderate hypertension

Next Previous
X
Search
Trial Profile

Randomized, controlled, parallel arm, PROBE study to evaluate different effects of imidapril and candesartan [candesartan cilexetil] on fibrinolysis and insulin-sensitivity in patients with mild to moderate hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imidapril (Primary) ; Candesartan cilexetil
  • Indications Essential hypertension; Hypertension
  • Focus Pharmacodynamics
  • Acronyms FISIC

    • Most Recent Events

    • 01 Apr 2011 Results published in Hypertension Research.
    • 30 Aug 2009 Results were presented at the Annual Congress of the European Society of Cardiology (ESC) meeting.
    • 12 Apr 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top